Business Context and Reporting Period
Company: Akers Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 21, 2018
Reporting Period: The filing addresses the quarter ended March 31, 2018, and potentially prior periods.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses on a procedural delay regarding financial reporting rather than disclosing new financial results.
Material Changes and Events
- Delayed Filing: The Company is unable to file its Form 10-Q for the quarter ended March 31, 2018, as scheduled.
- Reason for Delay: The Company is conducting an ongoing review of the characterization of certain revenue recognition items for the quarter ended March 31, 2018.
- Scope Expansion: The review has expanded to include certain transactions in previous quarters.
- Timeline: The completion date for the review cannot be estimated at this time.
Outlook, Risks, and Management Commentary
Management Commentary: Following the completion of the review, the Company will file the delayed 10-Q and determine whether it needs to revise, correct, or restate reports for any previous quarter or fiscal year.
Risks and Contingencies: There is a material risk that prior financial statements may require restatement depending on the outcome of the revenue recognition review. The uncertainty regarding the timeline for the review creates reporting delays.
Investor Verification Checklist
- Verify the specific revenue recognition items under review and their potential financial impact.
- Monitor for the eventual filing of the Form 10-Q for the quarter ended March 31, 2018.
- Watch for announcements regarding any required restatements of prior period financial reports.
- Confirm if the scope of the review expands further beyond the currently identified transactions.